Kine C3 : unique platform for drugs targeting the CNS

 

Cynbiose has developed the proprietary KineC3 platform©: this platform is dedicated to the study of the crossing of the blood-brain barrier (BBB) for drug candidates targeting the central nervous system. The implementation of different in vivo exploration techniques and methods enable detailed central pharmacokinetics studies to be carried out.

 

Our proprietary methods are based on :

  • Ethical and technical control of cerebrospinal fluid sequential (CSF) sampling in non-human primate (NHP) to perform comprehensive exploratory pharmacokinetic studies on the central nervous system (CNS) during periods ranging from 30 minutes to several days, with blood sampling point carried out in parallel.

 

  • Cerebral microdialysis (CMD) to monitor and measure regional brain biochemistry in conscious primates. It also allows drug injection in very specific parts of the brain, and avoids any possible interference associated with animal anesthesia. This technique offers the opportunity to run pharmacokinetic studies in brain extracellular fluid (ECF) , which can be coupled with analyses of cerebrospinal fluid and circulating blood.

 

Fore more information, please go to through our scientific publications.

Share this!